One person walks next to a sign that says, “The vaccine is the best shot against COVID-19” on the Upper West Side amid the March 30, 2021 coronavirus pandemic in New York City.
Noam Galai | Getty Images
Johnson & Johnson privately asked rivals Pfizer and Moderna of the Covid-19 vaccine to join a study on the potential risk of blood clots, but companies declined, The Wall Street Journal reported Friday. quoting people familiar with the matter.
Pfizer and Moderna executives said their vaccines seemed safe and saw no need to redouble the efforts of regulators and companies already studying the rare issue of blood clots, according to the magazine’s report.
Only AstraZeneca, whose vaccine has also raised regulators’ concern about blood clots, agreed to join the effort, the newspaper said.
CNBC has contacted all four companies to comment.
On Tuesday, the Food and Drug Administration and the Centers for Disease Control and Prevention advised states to temporarily pause the use of the J&J vaccine “with great caution” after six women developed a disorder. of blood clotting, potentially life-threatening left one dead and one in critical condition.
The women developed the disease known as cerebral venous sinus thrombosis (CVST) within about two weeks of receiving the shot, U.S. health officials told the press. CVST is a rare form of stroke that occurs when a blood clot forms in the venous sinuses of the brain. Finally, it can filter blood to brain tissue and cause bleeding.
On Wednesday, a CDC group decided to postpone a decision on the use of the J&J vaccine while officials investigated the cases.
Read the full Wall Street Journal report here.